WuXi Begins Construction of New R&D and cGMP Manufacturing Campus in Changzhou

We are pleased to announce that our manufacturing subsidiary, Syn-The-All (STA) Pharmaceuticals Co.,  has begun construction of  a new, fully integrated R&D and cGMP manufacturing site in Changzhou, about 10 miles...

WuXi Receives 2013 Lilly Global Supplier Award

We are very pleased to announce that WuXi has received the 2013 Lilly Global Supplier Award.  It is the third time that WuXi has been honored with this annual award from...

WuXi Releases New Mobile App for Compound Sourcing

We are thrilled to introduce another mobile tool to enable innovation on-the-go, the LabNetwork mobile app.  The first of its kind, the app gives chemists and sourcing professionals the ability to search...

WuXi Breaks Ground on New Cell Therapy Manufacturing Facility in Philadelphia

We are excited to announce that we have begun construction on a new facility in Philadelphia for cGMP manufacture of allogeneic and autologous cell-based therapeutics.  The 45,000-square-foot facility, anticipated to become operational...

WuXi Corporate Venture Fund Invests in Innovative Cancer Imaging Business

We are delighted to share with you that  WuXi Corporate Venture Fund has contributed to a $6.85 million Series B round financing of Avelas Biosciences, Inc., a San Diego-based biotech that is developing an...

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

INNOVATION THAT MATTERS